INTS vs. EDIT, CGEN, TARA, NMRA, CHRS, LXEO, ALEC, CCCC, ENTX, and VXRT
Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include Editas Medicine (EDIT), Compugen (CGEN), Protara Therapeutics (TARA), Neumora Therapeutics (NMRA), Coherus BioSciences (CHRS), Lexeo Therapeutics (LXEO), Alector (ALEC), C4 Therapeutics (CCCC), Entera Bio (ENTX), and Vaxart (VXRT). These companies are all part of the "biological products, except diagnostic" industry.
Intensity Therapeutics, Inc. Common stock vs.
Editas Medicine (NASDAQ:EDIT) and Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics, Inc. Common stock shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 18.6% of Intensity Therapeutics, Inc. Common stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Editas Medicine received 306 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 100.00% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 53.47% of users gave Editas Medicine an outperform vote.
Intensity Therapeutics, Inc. Common stock has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Intensity Therapeutics, Inc. Common stock, indicating that it is currently the more affordable of the two stocks.
Intensity Therapeutics, Inc. Common stock has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. Editas Medicine's return on equity of -80.13% beat Intensity Therapeutics, Inc. Common stock's return on equity.
In the previous week, Editas Medicine had 10 more articles in the media than Intensity Therapeutics, Inc. Common stock. MarketBeat recorded 14 mentions for Editas Medicine and 4 mentions for Intensity Therapeutics, Inc. Common stock. Intensity Therapeutics, Inc. Common stock's average media sentiment score of 1.89 beat Editas Medicine's score of 0.76 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the news media.
Editas Medicine presently has a consensus price target of $6.54, suggesting a potential upside of 303.61%. Intensity Therapeutics, Inc. Common stock has a consensus price target of $8.50, suggesting a potential upside of 1,417.86%. Given Intensity Therapeutics, Inc. Common stock's stronger consensus rating and higher possible upside, analysts clearly believe Intensity Therapeutics, Inc. Common stock is more favorable than Editas Medicine.
Editas Medicine has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Intensity Therapeutics, Inc. Common stock has a beta of 4.03, indicating that its stock price is 303% more volatile than the S&P 500.
Summary
Intensity Therapeutics, Inc. Common stock beats Editas Medicine on 10 of the 17 factors compared between the two stocks.
Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intensity Therapeutics, Inc. Common stock Competitors List
Related Companies and Tools
This page (NASDAQ:INTS) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy INTS Stock Free INTS Stock Alerts